In the STEP 1, 2, and 3 trials in adults with overweight or obesity, with and without type 2 diabetes, treatment with semaglutide 2.4 mg resulted in significant reductions in CRP concentrations compared with placebo, irrespective of BMI or baseline bodyweight. The gene discussed is CRP; the disease is type 2 diabetes mellitus.